CYP3A phenotyping provides a means for personalized drug therapy. We focused our attention on the plasma 6β-hydroxycortisol (6β-OHF) to cortisol ratio as an index for CYP3A phenotyping. In the present study, we developed a sensitive and reliable method for the simultaneous determination of 6β-OHF and cortisol in human plasma using high-performance liquid chromatography/tandem mass spectrometry together with picolinylester derivatization or nonderivatization methods and 6β-[9,11,12,12- H ]hydroxycortisol and [1,2,4,19- C ]cortisol as internal standards for in vivo CYP3A phenotyping in humans. The lower limits of quantification were 38.513 pg/mL for 6β-OHF and 38.100 pg/mL for cortisol. The relative error and relative standard deviation of the lower limits of quantification were <5% for both methods. The intra-day and inter-day assay reproducibilities of the determined 6β-OHF and cortisol concentrations were consistent with the actual amounts added as relative errors and relative standard deviations for both methods, which were <5.4% and <3.9%, respectively. Both methods were applied for the quantification of plasma 6β-OHF and cortisol concentrations in healthy subjects taking oral contraceptives. The absolute concentrations and time course of 6β-OHF and cortisol were found to be consistent when measured using the 2 methods. The ratio as an index for in vivo CYP3A activity decreased after 21 days of taking oral contraceptives for both methods. To the best of our knowledge, this is the first study reporting the detailed investigation of accuracy and precision in the simultaneous measurement of 6β-OHF and cortisol in human plasma using liquid chromatography/tandem mass spectrometry coupled with stable isotope dilution method, which can be applied to CYP3A phenotyping.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jms.4200DOI Listing

Publication Analysis

Top Keywords

cyp3a phenotyping
12
cortisol human
8
human plasma
8
6β-ohf cortisol
8
lower limits
8
limits quantification
8
sensitive simultaneous
4
simultaneous quantitation
4
quantitation 6β-hydroxycortisol
4
cortisol
4

Similar Publications

Effects of CYP3A4 Variants on Methadone Metabolism In Vitro.

Biomed Chromatogr

January 2025

Department of Clinical Laboratory, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.

In hepatic drug metabolism, cytochrome P450 (CYP450) enzymes, particularly CYP3A4, catalyze the majority of drug biotransformations, accounting for over 50% of the CYP450 family's metabolic capacity. This study aimed to assess the catalytic efficiency of 22 CYP3A4 allelic variants on the in vitro oxidative metabolism of methadone. We utilized a baculovirus-insect cell expression system to produce recombinant CYP3A4 variants and subsequently assessed their catalytic activity in the N-demethylation of methadone.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the role of the major metabolite of artemisinin (ART), 10β-hydroxyartemisinin (ART-M), in its effectiveness against malaria.
  • Both ART and ART-M were tested against two strains of Plasmodium, with results showing that although ART-M had a weaker direct potency, it achieved higher concentrations in the body.
  • The findings suggest that ART-M plays a significant role in the overall efficacy of ART, highlighting the importance of considering this metabolite in treatment protocols.
View Article and Find Full Text PDF

Background And Objective: Voriconazole (VRC), a broad-spectrum antifungal drug, exhibits nonlinear pharmacokinetics (PK) due to saturable metabolic processes, autoinhibition and metabolite-mediated inhibition on their own formation. VRC PK is also characterised by high inter- and intraindividual variability, primarily associated with cytochrome P450 (CYP) 2C19 genetic polymorphism. Additionally, recent in vitro findings indicate that VRC main metabolites, voriconazole N-oxide (NO) and hydroxyvoriconazole (OHVRC), inhibit CYP enzymes responsible for VRC metabolism, adding to its PK variability.

View Article and Find Full Text PDF
Article Synopsis
  • A study aimed to identify factors influencing the required dose of tacrolimus in adult kidney transplant recipients during their first year post-transplant, focusing on blood concentration ratios across different time periods (D4-D7, D8-M3, M3-M12).
  • Key factors impacting tacrolimus dosage included patient age, end-stage renal disease, CYP3A phenotype, and specific blood measurements, together explaining over 72% of the variability in drug concentration early on.
  • The research found that donor age and CYP3A phenotype also affected dosage in the later follow-up periods, while varying effects of baseline health conditions were noted, but no significant ethnicity or food influences were found.
View Article and Find Full Text PDF

Background: Cariprazine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6.

Aim: This study aimed to evaluate the effects of erythromycin, a moderate cytochrome P450 (CYP)3A4 inhibitor, on the pharmacokinetics of cariprazine in male patients with schizophrenia, and to assess the influence of CYP2D6 phenotypes on cariprazine metabolism.

Methods: Forty-two patients received oral doses of 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!